Nothing Special   »   [go: up one dir, main page]

MX2021007677A - Proteinas de union multiespecificas basadas en pseudofab. - Google Patents

Proteinas de union multiespecificas basadas en pseudofab.

Info

Publication number
MX2021007677A
MX2021007677A MX2021007677A MX2021007677A MX2021007677A MX 2021007677 A MX2021007677 A MX 2021007677A MX 2021007677 A MX2021007677 A MX 2021007677A MX 2021007677 A MX2021007677 A MX 2021007677A MX 2021007677 A MX2021007677 A MX 2021007677A
Authority
MX
Mexico
Prior art keywords
binding proteins
pseudofab
multispecific binding
domain
multispecific
Prior art date
Application number
MX2021007677A
Other languages
English (en)
Inventor
Christian Beil
Christian Lange
Ercole Rao
Thomas Langer
Gerhard Hessler
Wulf- Dirk Leuschner
Nadja Spindler
Soraya Hoelper
Sandra Weil
Karl- Christian ENGEL
Cendrine Lemoine
Bruederle Sevim Oezguer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18306840.2A external-priority patent/EP3674319A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021007677A publication Critical patent/MX2021007677A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan proteínas de unión que comprenden un dominio pseudoFab que incluye un dominio inactivado estabilizado y un segundo VH/VL que forman un primer dominio de unión a antígeno funcional. También se proporcionan proteínas de unión multiespecíficas que comprenden al menos un pseudoFab. También se proporcionan proteínas de unión multiespecíficas, ácidos nucleicos que codifican proteínas de unión y proteínas de unión multiespecíficas, vectores de expresión, células hospederas, una composición farmacéutica y métodos de tratamiento administrando las proteínas de unión o proteínas de unión multiespecíficas descritas en la presente memoria.
MX2021007677A 2018-12-24 2019-12-23 Proteinas de union multiespecificas basadas en pseudofab. MX2021007677A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306840.2A EP3674319A1 (en) 2018-12-24 2018-12-24 Pseudofab-based multispecific binding proteins
EP19305813 2019-06-21
PCT/IB2019/061304 WO2020136564A1 (en) 2018-12-24 2019-12-23 Pseudofab-based multispecific binding proteins

Publications (1)

Publication Number Publication Date
MX2021007677A true MX2021007677A (es) 2021-12-10

Family

ID=69174547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021007677A MX2021007677A (es) 2018-12-24 2019-12-23 Proteinas de union multiespecificas basadas en pseudofab.

Country Status (15)

Country Link
US (2) US11739160B2 (es)
EP (1) EP3902825A1 (es)
JP (1) JP2024504880A (es)
KR (1) KR20220015369A (es)
CN (1) CN114885609A (es)
AU (1) AU2019416895A1 (es)
BR (1) BR112021012337A2 (es)
CA (1) CA3124770A1 (es)
CO (1) CO2021009025A2 (es)
IL (1) IL284317A (es)
MA (1) MA54601A (es)
MX (1) MX2021007677A (es)
SG (1) SG11202106393SA (es)
TW (1) TW202041534A (es)
WO (1) WO2020136564A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007677A (es) 2018-12-24 2021-12-10 Sanofi Sa Proteinas de union multiespecificas basadas en pseudofab.
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5732168A (en) 1995-10-31 1998-03-24 Hewlett Packard Company Thermal optical switches for light
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2005313971B2 (en) 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
JP5364870B2 (ja) 2005-08-19 2013-12-11 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
AR060070A1 (es) 2006-03-24 2008-05-21 Merck Patent Gmbh Dominios proteicos heterodimericos obtenidos por ingenieria
EP3345616A1 (en) 2006-03-31 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US20120009182A1 (en) 2008-12-23 2012-01-12 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
KR102010827B1 (ko) 2009-06-26 2019-08-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
SI2522724T1 (sl) 2009-12-25 2020-07-31 Chuqai Seiyaku Kabushiki Kaisha Postopek za spremembo polipeptida za čiščenje polipetidnih multimerov
TR201903279T4 (tr) * 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
EP2606064B1 (en) 2010-08-16 2015-02-25 NovImmune S.A. Methods for the generation of multispecific and multivalent antibodies
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
TWI671315B (zh) 2011-03-28 2019-09-11 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2767135T3 (es) 2011-10-19 2020-06-16 Novimmune Sa Métodos para purificar anticuerpos
JP6541974B2 (ja) 2011-12-20 2019-07-10 メディミューン，エルエルシー 二重特異的抗体足場用改変ポリペプチド
DK2825559T3 (da) 2012-03-13 2019-06-03 Novimmune Sa Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CN104968685A (zh) 2012-09-25 2015-10-07 格兰马克药品股份有限公司 异源二聚免疫球蛋白的纯化
WO2014106004A2 (en) 2012-12-28 2014-07-03 Abbvie, Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
CA2922979A1 (en) 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
US10160812B2 (en) * 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
EP3143043B1 (en) * 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
WO2015188135A1 (en) 2014-06-06 2015-12-10 The California Institute For Biomedical Research Constant region antibody fusion proteins and compositions thereof
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
EP3227332B1 (en) * 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
AU2016232349B2 (en) 2015-03-13 2022-01-20 Novimmune Sa Methods of purifying bispecific antibodies
WO2017005649A1 (en) 2015-07-09 2017-01-12 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
MA50188A (fr) * 2017-09-22 2021-06-02 Wuxi Biologics Ireland Ltd Nouveaux complexes polypeptidiques bispécifiques
EP3674319A1 (en) 2018-12-24 2020-07-01 Sanofi Pseudofab-based multispecific binding proteins
MX2021007677A (es) 2018-12-24 2021-12-10 Sanofi Sa Proteinas de union multiespecificas basadas en pseudofab.
US20230103563A1 (en) * 2020-03-30 2023-04-06 Sanofi Split ch2 domains
EP4303231A1 (en) * 2021-02-07 2024-01-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody

Also Published As

Publication number Publication date
MA54601A (fr) 2022-03-30
JP2024504880A (ja) 2024-02-02
BR112021012337A2 (pt) 2021-09-14
CO2021009025A2 (es) 2021-12-10
KR20220015369A (ko) 2022-02-08
CN114885609A (zh) 2022-08-09
EP3902825A1 (en) 2021-11-03
CA3124770A1 (en) 2020-07-02
US20200255540A1 (en) 2020-08-13
US11739160B2 (en) 2023-08-29
IL284317A (en) 2021-08-31
TW202041534A (zh) 2020-11-16
SG11202106393SA (en) 2021-07-29
AU2019416895A2 (en) 2021-09-09
AU2019416895A1 (en) 2021-08-12
US20230391888A1 (en) 2023-12-07
WO2020136564A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
MX2023007045A (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) y metodos de uso de los mismos.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CY1122035T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
MX2024004646A (es) Proteinas de union de cadena unica de fragmento variable cd3.
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
PH12019500596A1 (en) Recombinant binding proteins and their use
MX2023000818A (es) Anticuerpos anti-antigeno 4 del linfocito t citotoxico (ctla-4) y metodos para uso de los mismos.
EP3795676A4 (en) APPLICATION OF B. FRAGILIS OR AKKERMANSIA MUCINIPHILA IN THE PREPARATION OF A MEDICINE INTENDED FOR PREVENTING OR TREATING A TUMOR
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
PH12020551716A1 (en) Anti-ror antibody constructs
MX2021007672A (es) Proteinas de union multiespecificas con dominios fab mutantes.
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
MX2018005154A (es) Anticuerpos de dominio unico dirigidos contra el virus de la inmunodeficiencia humana.
MX2021007677A (es) Proteinas de union multiespecificas basadas en pseudofab.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
MX2021015766A (es) Nuevos antigenos y metodos contra el cancer.
WO2020086479A9 (en) Dosing